The Norwegian Cancer Society and the Research Council have invested their resources for a remarkable initiative of a Nordic Cancer Research and will be giving funding of NOK 12 million for the Nanoyield research and development project.
Funding is provided to advance Alpha37, targeted Alpha therapy for the treatment of B-cells cancer. The project of Nordic Nanovector is focused on the advance production of Nordic Nanovector’s CD37 which targets antibody NNV003. CD37 is a target for B-cell malignancies; it is selectively expressed on the B-cell malignancies and B lymphocytes’ surface.
CD37-specific antibody NNV003 is a part of the Alpha37 radioimmunoconjugate. The project will be executed with the collaboration of one of the largest research institutes of Europe; SINTEF Biotechnology.
Recently a Europe’s wide research and development funding program; Eurostars, gave funding of EUR 0.6 million to the Nanovector’s project.
Radioimmunoconjugate Alpha 37 consists of CD-37 specific antibody NNV003 chelated with alpha particles generated by lead-212 which is being made in the research and development area with the collaboration of Orano Med. A single injection
Alpha37 shows a promising anti-cancer activity and it is well-tolerated as supported by the studies. Preclinical study outcomes presented at the International Cancer Congresses during the previous 12 months gave the pieces of evidence in the support of Alpha37. Survival improvement was observed in the preclinical models of CD37 positive non- Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
212Pb-NNV003 shows an encouraging toxicity profile, high efficacy and having a recoverable and reversible effect on platelet count and body weight. A single injection administration resulted in increased life expectancy. It is an effective and safe treatment for CD37 positive malignancies.
One of the scientific officers of Nordic Nanovector, Jostein Dahle showed gratitude on receiving non-dilutive funding from the Norwegian Research Council for the advancement of Alpha therapy. Moreover, he emphasized the importance of Alpha radionuclides and said that these radionuclides have shown a high potential for cancer therapies.
The high energy of Alpha-emitted radionuclides is limited so it results in localized cytotoxicity and doesn’t harm the healthy tissues. There are encouraging and strong preclinical shreds of evidence showing the good potential of Alpha37 for targeted cancer treatments such as to treat NHL and CLL.
Jostein Dahle said that with the collaboration of their partners, they are aimed for the advancement of this new candidate with more clinical trials.
According to an estimate, every year above 90,000 cases of CLL and NHL are reported in the United States. As collaboration is essential for control, Nordic ministers have joined forces and taking new steps for the treatment of B-cell malignancies. The Nordic Nanovector is aimed at the development of innovative treatments to address major medical requirements and to provide advanced care to cancer patients.
This huge investment by the Norwegian Research Council promotes Nordic research and supports the clinical trials to help the cancer patients to access the latest therapies. This historic initiative will promote the progress of innovations.